Clinical Trial Update: A Long-Term Extension Trial From Late Phase II of SPM 962 in Patients With Restless Legs Syndrome [Phase 2]

View source ↗

Summary

A long-term extension of a late-stage Phase II trial evaluating SPM 962 in idiopathic restless legs syndrome has completed, with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Restless Legs Syndrome

Drugs mentioned

• SPM 962

Snippet

Sponsor: Otsuka Pharmaceutical Co., Ltd. | Conditions: Idiopathic Restless Legs Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2014-04-23